Aegerion starts Japanese Phase III trial of cholesterol drug

|About: Aegerion Pharmaceuticals (AEGR)|By:, SA News Editor

Aegerion Pharmaceuticals (AEGR) has started a Phase 3 Trial in Japan to evaluate its Lomitapide treatment for cutting low-density lipoprotein ("bad") cholesterol (LDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

HoFH is a rare genetic disease that harms the ability of the body to remove LDL-C cholesterol. Sufferers often develop premature and progressive atherosclerosis, a narrowing or blocking of the arteries.

The trial adds to a Phase III study that has been completed in the U.S. and other countries.

Last year, Aegerion received orphan drug designation in Japan for Lomitapide. (PR)